Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suramin in Recurrent Malignant Primary Brain Tumors
NCT00002639Phase 2Completed
- Sponsor
- Emory University
- Start
- Jul 1995
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of suramin in glioblastoma multiforme (GBM), anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO) and 1 more, sponsored by Emory University. Primary endpoints: Radiographic Response, Time to Progression and 2 more. Started Jul 1995; status: completed.
02
Drugs
suramin
03
Conditions
glioblastoma multiforme (GBM)anaplastic astrocytoma (AA)anaplastic oligodendroglioma (AO)anaplastic mixed glioma (AOA)
Beyond the preview
Go deeper on NCT00002639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002639.